Disparities

/Disparities

Wealthy Advanced Prostate Cancer Men Live Longer

Men living in wealthier zip codes in the United States live longer with advanced prostate cancer than men in lower income zip codes.  Creighton University, Omaha, NE  researchers studied income levels and overall survival of men diagnosed with stage IV prostate cancer.  Lead author Sabra Ahmed and his team looked at 50,639 men in the National Cancer Database diagnosed with stage IV prostate cancer between 2004-2011 . Income was evaluated using the median income of the patient’s zip code.  Ahmed's abstract is being presented at the ASCO GU conference this weekend (Impact of income in stage IV prostate cancer. abstract #244) His conclusions: "Compared to [...]

By | February 15th, 2017|Advanced Prostate Cancer, disparities, Disparities, End-Of-Life|0 Comments

Prostate Cancer drugs cost more in the USA than in other countries.

The cost of Enzalutamide (Xtandi) in the United States is being challenged by Knowledge Ecology International (KEI), a public interest advocacy group.  The average US wholesale price of Xtandi in 2015 was $88 per capsule.   That can add up to $129,000 annual cost per man. There are significant issues related to high costs of treatment. The higher the cost, the more likely that insurance companies will  require pre-authorization to cover the cost of the drug.  That means a man dealing with advanced stage disease is tasked with asking his doctor to spend uncompensated time fighting the insurance company for his [...]

A Small Analysis of Abiraterone Responses in African American Men with Metastatic Castration Resistant Prostate Cancer

Presented at ASCO GU by Stolten and colleagues was abstract 244 that described the responses African American men had to abiraterone (Zytiga) in a retrospective cohort study of men seen at a single institution.  Stolten included differences in the men including their age at diagnosis, prior enzalutamide (Xtandi) and/or docetaxel (chemotherapy) use, as well as baseline alkaline phosphatase, hemoglobin, and lactate dehydrogenase.  The primary outcome of interest was duration of treatment with Zytiga and they considered velocity of PSA decline, PSA response and progression as a secondary outcomes. The treatment sample included 103 men with metastatic castration-resistant prostate cancer (mCRPC) [...]

More From ASCO GU 2016 – ExoDx™ Prostate(IntelliScore): A More Precise, Genetically Informed Prostate Cancer Test from a Simple Urine Sample

The constant hope and conversation of late has surrounded what is referred to as a liquid biopsy. The hope and goal is to no longer need to have an invasive needle biopsy to diagnose and stage prostate cancer. Biopsies are not accurate because there are too many false negatives, they only evaluate the actual tissue sampled and do not take into consideration the un-sampled tissue (which can have a different type or stage of cancer present). They also are painful and worse expose men to the possibility of infections, some of which can be life threatening. We dream of finding [...]